Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Drugs

Recall of Dornase alfa (Pulmozyme) - (Genentech, Inc) - 4/18/2001

DATE RECALL INITIATED:

April 18, 2001

PRODUCT / LOT NUMBER / EXPIRATION DATE:

Dornase alfa, Pulmozyme, Inhalation Solution

N9700A 2/2003

MANUFACTURER:

Genentech, Inc.
San Francisco, CA

REASON:

Genentech, Inc., is recalling the above mentioned lot of Dornase alfa, Pulmozyme, Inhalation Solution after discovering that Pulmozyme ampules were damaged during manufacturing. An investigation conducted by the firm disclosed that a small number of the ampules exhibited a tiny puncture resulting in leakage of the product. Pulmozyme is indicated for use in the treatment of Cystic Fibrosis.

 


The information in this listing reflects CBER's best efforts to communicate information that has been reported to FDA. Its accuracy and comprehensiveness cannot be guaranteed.

Page Last Updated: 10/04/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English